Acyline TFA, a GnRH peptide analogue, is a GnRH antagonist that inhibits gonadotropin and testosterone (T) levels.
Acyline (50 μg, s.c., twice daily, 5 days) TFA can result in disruption of vaginal oestrus and reduce uterine weights in female Kiss1−/−and Gpr54−/− mice, as well as a decrease in luteinizing hormone (LH) concentrations of female Kiss1−/− mice[1].
Acyline (50 μg, s.c., once) TFA can reduce follicle stimulating hormone (FSH) concentrations from pre-acyline 1.51 ng/mL to post-acyline 1.27 ng/mL in male Kiss1−/− mice and from pre-acyline 2.87 ng/mL to post-acyline 1.95 ng/mL in male Gpr54−/− mice[1].
References:
[1]. Y M Chan, et al. Kisspeptin/Gpr54-independent gonadotrophin-releasing hormone activity in Kiss1 and Gpr54 mutant mice. J Neuroendocrinol. 2009 Dec;21(12):1015-23.